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Abstract
Objective: Briefly to compare twin and multiple regions of interest (ROIs) in structural magnetic resonance images (sMRI), testing two statistical parametric mapping 
(SPM) packages against amyloid status in patients diagnosed with mild cognitive impairment (MCI), who underwent positron emission tomography with Pittsburg 
compound B (PiB-PET). The packages were Voxel-based specific regional analysis system for Alzheimer’s disease (VSRAD) and Brain anatomical analysis using 
DARTEL (BAAD). 
Subject data: Data on 65 patients diagnosed with MCI, who had undergone both sMRI scans and PiB-PET beta-amyloid imaging, were downloaded from the 
Alzheimer's disease neuroimaging initiative (ADNI) database. Of those 65 MCI cases, 18 were found positive by PiB-PET. 
Data processing: BAAD interprets sMRI both in false-color images and in Z-scores for 98 brain regions. VSRAD also gives a false-color picture, and one bilateral-
twin-ROI z-score, usually for the region of the hippocampus and entorhinal cortex, with ROI-locations specified in MNI coordinates. Results: Receiver operating 
characteristic (ROC) curves were used to measure the reliability of each set of ROIs by the area under the curve (AUC). VSRAD gave AUC around 0.68 with its 
default ROIs in the medial temporal lobe. With BAAD, AUC figures depended on the ROIs chosen; AUC values ranged from 0.69 for the hippocampal regions, via 
0.86 for 16 (bilateral) ROIs, to 0.98 or more with empirically selected (mostly unilateral) ROIs, not all contiguous. 
Conclusions: Our results indicated that the multi-ROI approach offers greater versatility and better discrimination of the amyloid-positive MCI cases, improving the 
prospect of data-acquisition and diagnosis earlier than the MCI stage. Both the number and selection of ROIs are crucial to accuracy. Further testing will be needed 
to validate ROI combinations for MCI and earlier stages, for other populations and pathologies, and for mixed pathologies.
Abbreviations and Acronyms: AD: Alzheimer’s disease; ADNI: 
Alzheimer's disease neuroimaging initiative; AGD: Argyrophylic 
grain disease; AUC: Area under the curve (i.e., under the receiver 
operating characteristics curve); BAAD: Brain anatomical analysis 
using DARTEL (version 2); DARTEL: Diffeomorphic anatomical 
registration through exponentiated Lie algebra (from the Wellcome 
Department of Imaging Neuroscience); DLB: Dementia with Lewy 
bodies; ERC: entorhinal cortex; FTD: Frontotemporal dementia (a 
sort of FTLD); FTLD: Frontotemporal lobar degeneration; HCScl: 
Hippocampal sclerosis; hsAD: hippocampus-sparing AD; JMP: 
statistical software (JMP 7.0 from SAS Institute, North Carolina, 
USA); LBD: Lewy body dementia; MCI: Mild cognitive impairment; 
MNI: Montreal Neurological Institute; MRI: Magnetic resonance 
imaging; Multi-ROI: More than one region of interest, usually more 
than one per side; ROC: Receiver operating characteristics analysis; 
ROI: Region of interest (similar to VOI, volume of interest); SD: 
Semantic dementia, a variety of FTLD; Twin-ROI: only one region 
of interest on each side, approximately symmetric, e.g., left + right 
entorhinal cortex; sMRI: Structural magnetic resonance imaging; 
SPM: Statistical parametric mapping (SPM8 in this study, from the 
Wellcome Department of Imaging Neuroscience, London, United 
Kingdom); SUVR: Standard uptake value ratio, in PiB-PET, a pseudo-
quantitative measure of amyloid concentration; VaD: Vascular 
dementia; VBM: Voxel-based morphometry; VOI: Volume of interest 
(similar to ROI, region of interest); VSRAD: Voxel-based specific 
regional analysis system for Alzheimer’s disease (Advance version) 
Introduction
The known causes of dementia are many. Alzheimer’s disease 
(AD) is the most common cause in most populations, and AD-type 
pathological changes (including amyloid and tau metabolism) begin 
many years before symptoms; the earlier they and other pathologies can 
be identified, the better for study and for intervention. It is important 
also to distinguish those who show poor cognitive abilities (many only 
temporarily) but are otherwise normal. Amyloid imaging by PET is 
very effective for identifying AD-type pathology, and PET data were 
used in this study, but PET is expensive and less available than MRI. 
MRI, though not cheap, is non-invasive and safe, and while still under 
development it may offer advantages; it has even been described as an 
ideal tool for whole-brain assessment [1]. 
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distribution for every voxel (a tissue probability map). The model is 
then compared to a patient’s MRI image or to another combined model 
of a sample or population, and the software calculates the differences 
in terms of standard deviations between the model brain and the other 
brain or model; a positive z-score in this context indicates atrophy in 
the subject. In the twin-ROI approach only two ROIs are described, 
one in each side of the brain, typically with an averaged z-score. In a 
multi-ROI approach more regions are processed, and not necessarily 
bilaterally. 
One package, Voxel-based Specific Regional analysis system for 
Alzheimer’s Disease (VSRAD, http://www.vsrad.info/index2.html, 
in Japanese), has been described as synonymous with “SPM8 plus 
DARTEL” [8]. It was developed by Matsuda et al., [9] and with further 
developments has been available and widely used in Japan for some 
years [10]. It was intended to optimise the signal-to-noise ratio by 
focusing on a bilateral twin region or volume of interest (ROI or VOI). 
A typical false-colour map in VSRAD shows a false-coloured patch in 
each side of a mostly grayscale brain. As the name implies, it is largely 
used for identifying AD-type pathology. The VSRAD ROIs can be 
placed anywhere, but they are usually in the region of the entorhinal 
cortex and hippocampus, where SPM maps of a sample population 
indicate the greatest Z-scores early in AD-type pathology cases. The 
VSRAD default ROI location is thus empirically derived, and need not 
match standard anatomical boundaries [10].
Brain Anatomical Analysis using DARTEL (BAAD) (http://www.
shiga-med.ac.jp/~hqbioph/saito/BAAD%28English%29.html) is under 
continuing development, also by a research group in Japan. If VSRAD 
may be described as “SPM8 plus DARTEL”, so too may BAAD, but with 
the addition and integration of three further software toolkits onto that 
SPM base: Wfu_Pickatlas (Maldigian et al., http://fmri.wfubmc.edu/
software/PickAtlas), MarsBaR (MARSeille Boîte À Région d’Intérêt; 
Brett et al., MarsBaR region of interest toolbox for SPM http://marsbar.
sourceforge.net), and XjView (a viewing program for SPM, http://www.
alivelearn.net/xjview8/). Other aspects of improving signal-to-noise 
ratios arise in BAAD processing: BAAD uses maximum-likelihood 
estimation (MLE) and maximum a-posteriori (MAP) algorithms for 
more complete and accurate segmentation, and MarsBaR re-calculates 
t-values within each region, to avoid any masking threshold effect in 
order to improve accuracy. BAAD is supplied with a standard dataset 
copied from the IXI database (Information Extraction from Images, 
Control Group IXI7080), but with the option to use any alternate 
dataset to suit a target population. 
ROC curves (Figures 1-6) were plotted by comparing the Z-scores 
calculated by BAAD and VSRAD against the PiB-PET results, and 2x2 
contingency scores (Table 1) were calculated using JMP software (SAS, 
http://www.jmp.com/en_us/home.html).
Results 
ROC curves were plotted to measure the reliability of each selection 
of ROIs, so that the area under each curve (AUC) accounts for positive 
and negative, true and false results. We found the results listed here, 
and calculated sensitivity and other measures by 2x2 contingency 
tables as shown in Table 1: 
ROI selection 1. With the VSRAD default ROI in the hippocampal/
entorhinal vicinity, AUC = 0.679 (Figure 1).
The AUC results of BAAD varied according to the ROIs selected: 
ROI selection 2. BAAD using only the bilateral anterior and 
  Good information may allow good decisions, and SPM can yield 
plenty of information, but the questions are how much of it to use, 
and how. For the maximum signal-to-noise ratio, one can focus on 
the region or regions expected to show the earliest atrophic changes. 
In typical AD-type pathology, this mostly means the medial temporal 
lobe, especially the entorhinal cortex and hippocampus [2-4]. VSRAD, 
widely trusted in Japan, uses an empirically-selected bilateral twin ROI 
in the entorhinal/hippocampal vicinity [5].
However, for a number of reasons, that region is neither a perfect 
biomarker nor necessarily sufficient. More brain data may be needed 
for better and earlier differentiation; for additional data from other 
regions to be explored, and for data to be compared between studies 
and between centers, thorough use of atlas-based regions is vital. BAAD 
was designed to give unbiased data for all 90 of the MNI atlas regions 
plus eight extras, and to use data from any number and combination 
of those regions.
This study reports the results of testing twin and multiple ROIs 
against a publicly available sample from the ADNI database. 
Objective 
The aim of this study was to make a pilot assessment of the 
relative merits of twin versus multiple regions of interest in diagnostic 
neuroimaging through statistical parametric mapping (SPM) from 
structural magnetic resonance images (sMRI), using two software 
packages: VSRAD and BAAD. These were both tested with sMRI data 
against amyloid-positive and amyloid-negative findings in a data-set 
provided by the Alzheimer's Disease Neuroimaging Initiative (ADNI). 
One package, VSRAD, has been available and widely used in Japan 
for some years, and the other, BAAD, is under development by a group 
of researchers, also in Japan. 
Subject data 
A set of data representing 65 patients (mean age 75 ± 8 y/o, mean 
MMSE score 27 ± 2) diagnosed with mild cognitive impairment (MCI) 
who had undergone both structural sMRI scans and amyloid imaging by 
Pittsburg compound B (PiB) positron emission tomography (PET) was 
downloaded from the ADNI database. (Group name; Upitt - PIB PET 
Analysis [ADNI1], address <https://ida.loni.usc.edu/pages/acccess/
studyData.jsp?categoryId=148&subCategoryId=34>, page date 2014). 
PiB-PET is not absolutely quantitative, and a SUVR threshold was set 
at 1.5, defining all cases with values below 1.5 as amyloid-negative and 
thus not representative of AD-type pathology, while all cases (n=18) 
scoring over 1.5 were considered likely to be representative of AD-
type pathology.  Of the MCI patients who were initially classified as 
amyloid-negative by PiB-PET, 3 showed an increase in SUVR from 
below to above 1.5 during the year after their initial consultation, but 
they were classified as negative because that was their status at the time 
of their MRI. 
Data processing 
Voxel-based morphometry (VBM) is an analytical approach 
intended to assess every voxel of a brain image “on a voxel-by-voxel 
basis” [6,7]. Statistical parametric mapping (SPM) was developed for 
VBM interpretation, and this report describes two software packages 
founded on SPM8 software produced by the Wellcome Department of 
Imaging Neuroscience, London, UK. SPM relies on the compilation, 
via segmentation and registration, of a template brain from a sample of 
a population, complete with a statistical model of MRI signal intensity 
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fusiform gyrus, plus inferior temporal region (Figure 5, with 8 ROIs 
each side, for a total of 16 ROIs). AUC = 0.860. 
ROI selection 6. BAAD with 11 ROIs (mostly unilateral) selected 
post hoc (“cherry-picking”) by stepwise forward selection logistic 
regression, tested against the sample from which they were derived. 
(Figure 6, with the following ROIs: left anterior hippocampus, right 
BA28, (part of the entorhinal region), left amygdala, right inferior 
frontal (the triangular part), middle frontal gyrus, left superior medial 
frontal, right superior medial frontal,  right inferior parietal lobe, left 
superior parietal lobe, left precuneus, left superior temporal pole.) 
AUC=0.979. 
ROI selection 7. BAAD with a different post hoc selection of 10 
ROIs: right BA28, left amygdala, left angular gyrus, left frontal inferior 
operculum, left superior medial frontal + right superior medial frontal, 
left middle occipital, left superior parietal, left Rolandic operculum, 
and left middle temporal pole. This alternate selection showed the 
posterior hippocampus regions (Figure 2, with 2 ROIs per side, for a 
total of 4 ROIs), AUC = 0.694.
ROI selection 3. BAAD using the bilateral hippocampus and 
entorhinal regions, (Figure 3, with 4 ROIs each side for a total of 8 
ROIs); AUC = 0.773. Given the nature of the VSRAD bilateral ROI 
derivation, one might expect AUC equal to VSRAD with this selection.
ROI selection 4. BAAD using 12 ROIs (those same bilateral 
hippocampus and entorhinal regions plus bilateral amygdala and 
parahippocampal gyrus). Figure 4, with 6 ROIs each side, for a total of 
12 ROIs). AUC = 0.861.
ROI selection 5. BAAD using those same bilateral hippocampus 
and entorhinal regions, plus amygdala, plus posterior cingulum, plus 
Figure 1. AUC=0.679. MCI differentiation (against PiB-PET status) by VSRAD with 
default ROIs.
Figure 2. AUC=0.694. MCI differentiation (against PiB-PET status) by BAAD using 
z-scores in these ROIs: Anterior hippocampus + posterior hippocampus, bilaterally (total: 
4 ROIs). This is a slightly better AUC than achieved by VSRAD, which is unexpected 
because VSRAD uses a default ROI empirically derived for maximum accuracy. One 
possible reason would be differences between the ABP database built into VSRAD and the 
IXI database used by default in BAAD, and another would be the extra software (MLE and 
MAP described above) intended to improve accuracy in BAAD.
Figure 3. AUC=0.773. MCI differentiation (against PiB-PET status) by BAAD using 
z-scores in these bilateral ROIs: Anterior hippocampus + posterior hippocampus + Ba28 
+ BA34 (total = 8 ROIs).
Figure 4. AUC=0.8611. MCI differentiation (against PiB-PET status) by BAAD using 
z-scores in these bilateral ROIs: anterior hippocampus + posterior hippocampus + Ba28 + 
BA34 + amygdala + parahippocampal gyrus (total = 12 ROIs)
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best performance overall, though with fewer ROIs than sets 5 and 6. 
Pending validation, this nevertheless seems to indicate considerable 
potential for improved performance using ROI-selections calculable 
from atlas-based morphometry. AUC=0.989.
ROI selection 8. BAAD with a third post hoc selection of 8 ROIs: 
left anterior hippocampus, left amygdala, right inferior triangular 
frontal, right middle frontal, left inferior parietal, left superior parietal, 
left superior temporal pole, right thalamus. AUC=0.94. This showed 
an improvement in test scores, not only over the twin-ROI VSRAD 
results, but also over ROI set 5, while using only half as many ROIs 
as set 5. This also will require external validation when further data 
become available.
Notably, not all these ROIs are contiguous, nor are the selections 
intuitively obvious. The precuneus is particularly distant from the 
hippocampus/entorhinal regions, and the precuneus cannot reasonably 
be included in a twin-ROI approach without abandoning the main 
target areas. 
Discussion 
Test results such as AUC, specificity, and accuracy scores vary 
greatly with the parameters of each test. The greater and more obvious 
the difference measured, the better the test seems to perform; the 
morphometric differences between AD patients and normal healthy 
controls are usually larger than between amyloid-positive and amyloid-
negative MCI, so any test applied to the former difference would seem 
to perform much better than if applied to the latter, because the sorts of 
memory impairment which attract a clinical diagnosis of MCI are likely 
to involve hippocampus dysfunction, which makes morphometric 
differential diagnosis more difficult. Many reports of morphometric 
assessment in the medial temporal vicinity show AUC and accuracy 
scores of at least 0.8 or 85%, and in 2005, Hirata et al. reported VSRAD 
scoring an AUC of almost 0.95 [9]. In the present report, VSRAD 
scored an AUC of only 0.68 against a more difficult target sample and 
with an unvalidated control group. VSRAD was included in the present 
study, partly to show whether the BAAD results were in a plausible 
range. 
The principle of focusing on the vicinity where the best signal-to-
noise ratio is expected (i.e., the hippocampus and entorhinal cortex 
for AD-type pathology), differentiates AD-type cases at a level widely 
considered acceptable, as in the ROC curves in Figures 1 and 2. The 
AUC values are approximately equal between VSRAD and BAAD, 
despite differences between the ROC curve shapes, which may be due 
to the difference in control groups and/or the slightly different ROI 
placements. The fact that the VSRAD result is not visibly better than 
BAAD despite using an empirically-derived (and hence presumably 
better) ROI may have been due to the difference in control groups, or 
to more accurate processing in BAAD, but considerable further testing 
may be needed to ascertain the effects of different control groups. 
As more of the significantly atrophic ROIs are added in BAAD, 
the AUC improves. A similar improvement is expected if the VSRAD 
ROIs are expanded to include more of the medial temporal lobes; 
with VSRAD, however, there would be no standard location, no atlas-
based z-score map, nor regional boundaries, all of which are useful or 
indispensable for multicenter studies. Researchers in other centers, 
perhaps using other acquisition protocols and even other software 
packages, should still be able to share and compare data using the same 
atlas standards; this is possible with BAAD due to the integrated atlas 
components. 
An important limitation of this study arises from the scarcity of data 
on sMRI + PET cases: the available cases are too few to allow external 
validation, so while the results presented here indicate considerable 
potentialities for accuracy, validation will have to wait for enlargement 
of the database. At the same time, the differences between the AUC 
scores, especially between figures 2 and 5 showing a 24% increase in 
AUC, or between figures 2 and 6 showing a 41% increase in AUC, do 
look very promising.
Comparing Figures 4 and 5, the AUCs show that not all regions 
are of equal value for differential diagnosis; the contribution of the 
parahippocampal gyrus seems approximately equal to the combined 
contribution of the posterior cingulum + fusiform gyrus + inferior 
Figure 5. AUC=0.860. MCI differentiation (against PiB-PET status) by BAAD using 
z-scores in these ROIs: anterior hippocampus + posterior hippocampus + Ba28 + BA34 + 
amygdala + posterior cingulum + fusiform gyrus + inferior temporal, bilaterally (total=16 
ROIs). Apparently the contribution of the parahippocampal gyrus is equivalent to that of the 
posterior cingulum + fusiform gyrus + inferior temporal regions here
Figure 6. AUC=0.979. MCI differentiation (against PiB-PET status) by BAAD using 
z-scores in these 11 ROIs selected post hoc but not yet validated: left anterior hippocampus, 
right BA28, (part of the entorhinal region), left amygdala, right inferior frontal, triangular 
part, right middle frontal gyrus, left superior medial frontal, right superior medial 
frontal, right inferior parietal lobe, left superior parietal lobe, left precuneus, left superior 
temporal pole.
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temporal. Evidently there may be a law of diminishing returns: more 
ROIs are better, but only in proportion to the quality of the signal 
acquired from each.
Figures 6-8 show remarkably high AUCs, from surprising and 
mostly unilateral selections of ROIs. Notably, not all these ROIs are 
contiguous; the precuneus is particularly distant from the hippocampus/
entorhinal regions, and cannot reasonably be included in a twin-ROI 
approach without abandoning the main target areas. These sets were 
selected by post hoc “cherry-picking”, and applied to the sample from 
which they were derived; while they need to be validated on further 
cases not yet available, the test scores are so much higher than the usual 
as to deserve some further investigation.
Although VSRAD allows improved AUC results  if one uses an 
expanded bilateral twin ROI, it lacks the versatility of a truly multi-ROI 
package both in use and in data-processing. This does not mean that its 
z-scores are not reliable in certain contexts; when Matsuda et al. greatly 
enlarged their VSRAD ROI across the medial temporal structures, their 
numerical results were of the same order as the better BAAD results 
reported here (see Supplemental Material below) [10].
Although a simple-shaped region can be described more or less 
adequately by its MNI coordinates and radial size, a standard atlas is far 
more useful for general purposes, and such a selection as that in Figure 
6 would probably only be derived from a range of atlas-based z-scores 
such as those automatically produced by BAAD. A map of places with 
the greatest z-scores could equally be produced in VSRAD, but only 
one ROI would have a numerical score attached, and no standard 
brain regions would be defined. There is no obvious reason for the 
unilaterality of so many ROIs giving this good result, and pending 
validation with further samples, we have to wonder whether this or 
anything like it will be as successful as it seems, and whether other non-
obvious selections might do better for other populations. In particular, 
we know of no reason to be confident that this particular set would 
be optimal for still earlier stages, and this would be a commendable 
prospective study project: if sufficient numbers of asymptomatic and 
early-MCI people can be imaged over a period of years, the optimal 
multi-ROI selections for very early warning may be deduced (perhaps 
with machine-learning). With the complete atlas-linked z-score data, 
finding patterns becomes a matter of statistical mathematics facilitated 
by the standardized brain regions. Despite a range of relevant studies, 
ROI Selection AUC AUC increase Sensitivity Specificity Accuracy Positive likelihood
Negative 
likelihood
PPV (post-test 
prob.)
ROI set 1 (VSRAD) 0.679 - 0.65 0.556 0.585 1.463 0.63 0.394
ROI set 2 (4 ROIs) 0.694 2.2% 0.65 0.622 0.631 1.721 0.563 0.433
ROI set 3 (8 ROIs) 0.773 13.8% 0.65 0.778 0.739 2.925 0.45 0.565
ROI set 4 (12 ROIs) 0.861 26.8% 0.65 0.8 0.754 3.25 0.438 0.591
ROI set 5 (16 ROIs) 0.860 26.7% 0.75 0.756 0.754 3.068 0.331 0.577
ROI set 6 (11 ROIs) 0.979 44% 0.8 0.867 0.846 6 0.231 0.727
ROI set 7 (10 ROIs) 0.989 45.7% 1 0.956 0.969 22.5 0 0.909
ROI set 8 (8 ROIs) 0.94 38.4% 0.8 0.844 0.831 5.14 0.237 0.696
Table 1. The results of AUC calculations and 2x2 contingency tables for various selections of ROIs, showing that figures for accuracy etc. may increase not only with increasing numbers of 
ROIs, but also with specific selections of ROIs. The best scores here were achieved with a post hoc selection of 10 ROIs, and even a select set of 8 ROIs gave a considerable improvement 
over the routine 8 ROIs. AUC: area under the ROC curve. AUC Increase: change relative to the VSRAD default result.
Figure 7. AUC=0.989. This is similar to Figure 6, but using z-scores in these 10 ROIs 
selected post hoc and not yet validated: right BA28, left amygdala, left angular gyrus, left 
frontal inferior operculum, left superior medial frontal + right superior medial frontal, left 
middle occipital, left superior parietal, left Rolandic operculum, and left middle temporal 
pole.
Figure 8. AUC=0.94. This too is similar to Figure 6, but using z-scores in these 8 ROIs 
selected post hoc and not yet validated: left anterior hippocampus, left amygdala, right 
inferior triangular frontal, right middle frontal, left inferior parietal, left superior parietal, 
left superior temporal pole, right thalamus.
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we believe that still not enough is known about z-score distributions 
in AD, nor in other pathologies in diverse populations, but the 
standardized BAAD range of data output seems to provide good 
research material for finding out. With long-term multi-center multi-
ROI studies, it may be possible to devise reliable SPM-based screening 
tests for AD and other pathologies even when the abnormal protein 
deposition is just beginning.
We suspect that it may be feasible to use spreadsheets of z-scores 
of atlas-based regions to deduce well-fitting profiles of atrophy 
distributions for other conditions too. It may further be feasible to 
compile contrasting templates to distinguish components in mixed 
pathologies.
Twin ROIs may seem enough. In neuroimaging, the signal-
to-noise ratio (a.k.a. source-to-noise ratio) can be maximized by 
measuring only the regions(s) showing the earliest/greatest change 
(the “signal” in sMRI being atrophy) for the pathology in question, 
while excluding other parts, and this is the VSRAD approach. In 
typical AD-type pathology the earliest atrophic changes measurable 
by sMRI are widely said to begin in the medial temporal region in the 
following sequence: (1) the entorhinal cortex, (2) hippocampus, (3) 
then amygdala, parahippocampus, and neocortex [2-4]. The first two of 
these regions seem obvious targets for morphometry or volumetry, and 
the hippocampus has been found easier to measure than the entorhinal 
cortex. Also, morphometrically detectable hippocampus damage 
corresponds with the most obvious feature of AD, which is loss of the 
ability to form memories [11-13]. 
The literature contains many commendations for the hippocampus 
as a biomarker; it is among the first regions to show damage in AD, both 
in terms of morphometrically detectable hippocampus damage [13,14] 
and in terms of accumulating amyloid plaques and neurofibrillary 
tangles very early in AD pathology [15,16]. Morphometrically 
detectable hippocampus atrophy has repeatedly been found predictive 
of cognitive decline or dementia [12]. Reportedly it may be detectable 
in the amnestic mild cognitive impairment (aMCI) stage, and even 
before symptoms are noticed, perhaps 10 years before dementia is 
usually diagnosed [17,18]. In later stages it correlates roughly with the 
severity of cognitive loss [19] and strongly with Braak and Braak stages 
of AD [20] As a biomarker for AD it has been commended variously, 
as “the best-established”, [21] “the most established... to date”, [22] and 
“one of the best…” [13]. 
VSRAD was developed to measure structural abnormality relative 
to a Japanese control-group (the “able-bodied person database” or 
ABPDB) in that relatively small, empirically-selected bilateral ROI 
in the hippocampus/entorhinal vicinity [5]. The obvious advantage 
of VSRAD’s small bilateral ROI is speed: one patient’s MRI data 
can be processed through VSRAD in a quarter of an hour or less, 
including input time, on a standard desktop PC running Windows 8. 
A disadvantage is that batch processing is not possible. Another is that 
VSRAD, in its current iteration, does not allow substitution of control 
groups alternative to the ABPDB. Also, as far as we know, no version is 
yet available in languages other than Japanese.
There may be some tendency for clinicians to think of dementia 
primarily in terms of AD, which is not wholly wrong if AD is present in 
very approximately two-thirds of dementia cases (actual figures varying 
greatly with the population). At the same time, one should remember 
that very approximately two-thirds of dementia patients suffer some 
other pathology, with or without AD. Bearing that in mind, the medial 
temporal region may not be the only location in which quantitive 
assessment might prove informative. There are other reasons too, not 
to trust hippocampus morphometry unreservedly.
Firstly, the hippocampus may not be where AD-related atrophy 
really starts; the sequence seems to be dorsal raphe before entorhinal 
cortex, then hippocampus, then amygdala, parahippocampus, and 
neocortex [2-4,15,23], and it may be that the posterior cingulate, and 
precuneus regions show atrophy very early too [24].
Secondly, hippocampus atrophy is non-specific. Each pathology 
might be expected to produce a more-or-less characteristic pattern of 
damage to be seen by structural neuroimaging, but these may overlap 
significantly in terms of tissues affected, so that atrophy of any part – 
such as the hippocampus – may be difficult to diagnose on its own. 
Hippocampus atrophy may be caused by various other pathologies, 
perhaps in addition to AD, including the following:
Argyrophylic grain disease (AGD), for example, is virtually 
impossible to distinguish from AD except in post-mortem histology, 
where it has been reported in 1-5% of AD patients [25]. Like AD, AGD 
damages the entorhinal cortex, hippocampus, and amygdala.
Frontotemporal dementia (FTD) is yet another cause of 
hippocampal region atrophy, and another example of the need to take 
other brain regions into account, to put the medial temporal region 
z-scores into perspective. Atrophy in the frontal and parietal regions 
may mean FTD [26,27]. 
Hippocampal sclerosis (HCScl) and AD have different aetiologies 
and rates of onset, [27,28] but are so similar in the distribution of 
atrophy which they cause in the entorhinal cortex, hippocampus, and 
amygdala, [29] and even in the hippocampus subfields —the CA1 and 
the subiculum [30] — and hence are so similar in effects, that 75% 
of HCScl cases are misdiagnosed as AD even at final diagnosis [29]. 
HCScl is not as rare as might be thought; it was the most common 
non-amyloid cause of suspected AD in an autopsy series, [31] and it 
has been found at autopsy in 5-30% of nonagenarians, [27] though as 
a single pathology at autopsy it has been reported in only 0.4% [30]. 
Because HCScl causes damage faster than expected from AD, it might 
be suspected in context of medial temporal changes disproportionate 
to those in other brain regions. In other words, for morphometric 
purposes there is little point in evaluating only the medial temporal 
regions and subregions, unless further regions are also evaluated to 
provide context. 
Semantic dementia (SD, a variety of FTLD) is another disease very 
closely resembling AD; AD and SD cause early and equal atrophy not 
just in the hippocampus, but also in the CA1 subfield, [18] rendering 
the CA1 per se as nonspecific for diagnosis as is the hippocampus in 
total. Again, some wider perspective is needed, such as a finding of 
atrophy in the speech areas, to distinguish early SD from early AD 
[18,27]. 
Vascular dementia (VD), perhaps the second-most-common cause 
of dementia, [32] and other cerebrovascular pathologies can cause 
hippocampus atrophy too [27]. 
The entorhinal cortex and hippocampus are not alone for long 
in AD. AD-type pathological changes are thought to begin many 
years before symptoms, and for the large majority of patients, testing 
begins only after symptoms start, by which stage other regions are also 
affected. For example, Scahill noted that the inferolateral temporal and 
medial parietal regions are already likely to be showing significantly 
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increased rates of atrophy when symptoms of AD-type pathology are 
noticed [17].
The ROC results in this paper show dramatic differences achieved by 
the inclusion of ROIs outside the entorhinal cortex and hippocampus— 
i.e., outside the default ROIs of VSRAD, and it is worth emphasising 
that the test cases chosen from ADNI were all MCI cases, and thus less 
atrophic and less easy to distinguish by sMRI than full AD cases would 
be. Even if one could somehow rule out all pathologies except the most 
common variety of AD, one still could not justify limiting sMRI to only 
the entorhinal cortex and hippocampus.
Some AD cases do not cause hippocampus atrophy; [33] some 
variation in incidence figures is to be expected, and Bobinski et al. 
reported only that “more than 90%” of AD cases show hippocampus 
shrinkage [34]. Hippocampus sparing AD (hsAD) confounds 
established twin-ROI interpretation. Murray et al. reported that 11% 
of all AD cases were hsAD, and of those 11% more than half were 
misdiagnosed as something other than AD [28]. The 3 types are 
distinguished by their distributions of excessive neurofibrillary tangles: 
frontal, parietal, and temporal. These cases tend to be misdiagnosed 
as frontotemporal dementia, corticobasal syndrome, and primary 
progressive aphasia respectively [28].
Other ROIs have been used in other studies; as the following 
6 sources illustrate, various ROIs beyond the usual entorhinal/
hippocampal vicinity have been found relevant to AD-type atrophy: 
Arimura et al. used cerebrospinal fluid (CSF) volume, cerebral cortical 
thickness, gray matter volume, and white matter volume [35]. Kidron 
et al. measured ventricular CSF volumes and temporal gray matter 
volumes [36]. Macdonald et al. measured the temporal horn and 
hippocampus [37].
Doré et al. measured cortical thickness in the posterior cingulate, 
precuneus and hippocampus [38]. Whitwell et al. noted involvement 
of the fusiform gyrus, the medial parietal lobe, and the middle and 
posterior temporal lobe [39]. 
 Kilimane et al. found significant volume reductions of all parts 
of the basal forebrain cholinergic system (BFCS), which were most 
marked in the posterior nucleus basalis Meynert (NbM). They 
reported: “Diagnostic accuracy of posterior NbM volume was superior 
to hippocampus volume... despite higher multicenter variability of the 
BFCS measurements.”[40]. 
BAAD in a real sense covers all those regions automatically; its 
combination of SPM, WFU_Pickatlas, MarsBAR, and xjView allows 
any desired selection of one or more anatomical brain regions, whether 
grey or white matter or CSF, unilateral or bilateral, plus measurements 
of intracranial volume and of CSF. Routinely, the MarsBaR stage yields 
a z-score for each of the 98 regions delineated or “masked” by PickAtlas; 
these are the standard 90 Montreal Neurological Institute (MNI) 
regions, plus 4 extra regions bilaterally: the anterior and posterior 
hippocampus and the BA28 and BA34 regions covering the entorhinal 
cortex, which extra regions were added to improve definition.
Causes of dementia may be classified in various ways, such as 
(a) reversible, (b) fixed, and (c) progressive, and in considering the 
possibilities it is well to remember at least two key facts. 
Firstly, the earlier the diagnosis, the better, and for good reasons. 
Some etiologies are at least partially reversible (e.g., metabolic 
disturbances, anti-AD drug overdose, hormone anomaly, vitamin 
deficiency, or normal pressure hydrocephalus); and against AD 
several drug treatments have already shown promise in counteracting 
functional changes in the brain and delaying the onset of symptoms, 
while other treatments are under research and development, but in 
every case, the sooner the pathology (whether typical or atypical) is 
identified, the better, not only for treatment but also for timely study 
and for preparations for the future. 
Secondly, no neurodegenerative disease is known to protect against 
any others; patients may suffer multiple, coexisting pathologies (or 
comorbidities), no two of which need be expected to begin at the same 
time, nor to progress at the same rate. The progressive or degenerative 
causes (some of which are described above as causing hippocampus 
atrophy) include the degenerative neuropathies or “brain destroying 
diseases” including: Alzheimer’s disease (AD), including 3 varieties 
of hippocampal-sparing AD (hsAD), argyrophylic grain disease 
(AGD), AIDS related dementia, alcohol-dementia, dementia with 
Lewy bodies, frontotemporal lobar degeneration (FTLD) including 
frontotemporal dementia (FTD), progressive nonfluent aphasia, and 
semantic dementia (SD), hippocampal sclerosis (HCScl), Creutzfeld-
Jakob disease (CJD) and the transmissible new variant CJD (nvCJD), 
Korsakoff’s psychosis, Lewy body dementia, Parkinson’s-associated 
dementia, primary progressive aphasia, progressive supranuclear 
palsy, subacute sclerosing panencephalitis, vascular dementia, and 
Wernicke’s encephalopathy. 
Absolute and relative incidence rates of pathologies vary with time 
and with populations, but none is so rare as to be unimportant to the 
patients who suffer it and to their carers and families. While AD is 
commonly described as the commonest cause of dementia, reported 
rates of AD vary so widely that in some populations vascular dementia 
(VaD) has been found more common than AD [41,42].
Figures for rates of multiple-cause dementias also vary, and while 
most reports put mixed states below the rate of pure AD, at least one 
source suggests that mixed states “are probably more usual than pure 
dementia syndromes” [42].
Much research is still needed on interactions of morbidities, but 
there have been suggestions that some, such as AD and VaD, may 
interact synergistically, and some may give entirely false indications 
if only a narrow biomarker range is used. For example, even precise 
monitoring of the entorhinal and hippocampus regions might be too 
narrow if a patient suffers hsAD plus VaD, or AD plus SD.
Conclusions 
Our results indicated that the multi-ROI approach exemplified 
by BAAD offers greater versatility in assessment and diagnosis than 
the twin-ROI approach represented by the originally single-purpose 
VSRAD, as well as facilitating information exchange between study 
centers, thanks to BAAD’s atlas components. 
One obvious limitation of this comparison between results obtained 
through BAAD and VSRAD was the mis-match between the groups: 
the ABP database in VSRAD, the IXI set in BAAD, and the population 
which gave rise to the ADNI database. This illustrates a fundamental 
requirement in SPM: Control groups from which templates are derived 
are crucial. BAAD allows substitution of any control database, allowing 
BAAD to be used anywhere, but presumably the software of VSRAD 
can be updated to allow similar adaptability, so this is not an inherent 
limitation in the approach. Another possible limitation was the use of 
PiB-PET amyloid-imaging; PiB-PET is usually accepted as indicative 
of AD, but there is still some lack of clarity about the roles of amyloid 
and tau, particularly regarding atrophy in the medial temporal regions, 
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which may be afflicted with tau changes before amyloid plaques. If tau-
imaging data had also been available, they would have been used. 
Even allowing for the limitations of this study, multi-ROI 
combinations showed better discrimination than did twin-ROI 
between the amyloid-positive and amyloid-negative MCI cases. 
Certain ROIs can contribute significantly more than others to 
accurate discrimination between etiologies. Although the “cherry-
picked” post hoc selections demonstrated in this paper should not be 
considered reliable until validated with further cases, their excellent 
initial scores seem to indicate considerable potential in multi-ROI 
combinations for this MCI context. Validation and further testing may 
also prove worthwhile if reliable databases can be developed for ROI 
combinations, in BAAD or any other multi-ROI system, to account 
for other populations, other pathologies than typical AD, and mixed 
pathologies. 
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Supplemental material on VSRAD ROIs 
  Our results showed that selectively increasing the number of 
ROIs in BAAD increased the accuracy of discrimination between PiB 
negative and positive cases. Matsuda et al. achieved a similar effect in 
VSRAD by expanding their VOI to include “medial temporal structures 
involving the entire region of the entorhinal cortex, hippocampus, and 
amygdala”, and reported accuracy of 91.6%, with specificity of 97.5% 
and sensitivity of 86.4% for cases of very mild AD [10]. Those figures 
were obtained with a Japanese population database appropriate to the 
Japanese patients, and so may be comparable to BAAD used with the 
ADNI cases, though since very mild AD should show more atrophy 
than MCI, better scores would be expected in this case. 
  An important distinction in this context is that expanding a twin 
ROI is equivalent to combining multiple standard MNI brain regions 
only when those regions are contiguous or very nearly so.
  VSRAD is widely used in Japan for diagnosis and research, having 
undergone continuing development since its introduction in 2005. 
VSRAD has been focused on various regions, as follows: 
1) The entorhinal cortex [43-45]
2) The medial temporal regions (including the entorhinal cortex) 
[9,46] 
3) The hippocampus region. [9,47-49] 
4) The amygdala + parahippocampus [50] 
5) The parahippocampus [51,52] 
6) White matter: [53] As in other brain regions, white matter 
damage is difficult to link specifically to any one cause, and white 
matter may show damage from three relatively common dementia-
causing pathologies: AD, DLB, and VaD [54]. Nakatsuka et al. used 
VSRAD to identify DLB-specific white matter atrophy, [55] showing 
that although VSRAD was named for its target pathology of AD, it can 
be applied anywhere, and for pathologies other than AD. So too, of 
course can BAAD.  
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